According to a new report, published by KBV research, The Global Companion Animal Arthritis Market size is expected to reach $3.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
The Other Arthritis segment is showcasing a CAGR of 8.6% during (2022 - 2028). It covers septic, polyarthritis, and rheumatoid arthritis diseases. Dogs with chronic rheumatoid arthritis experience excruciating joint pain and inflammation. Despite being less common than osteoarthritis, it has a substantial impact on small dogs and cats. In veterinary hospitals or clinics, it can be identified in dogs utilizing a canine rheumatoid factor immunologic test. The most effective medications for treating rheumatoid arthritis in companion animals are corticosteroids, cyclosporine, and NSAIDs.
The Veterinary Hospitals & Clinics segment acquired maximum revenue share in the Global Companion Animal Arthritis Market by Distribution Channel in 2021 thereby, achieving a market value of $1.5 billion by 2028. This is due to an increase in veterinary hospitals and clinics with cutting-edge infrastructures worldwide. The veterinary hospitals and clinics are essential for providing pet owners with quick diagnoses and assistance in determining the right dosage of arthritis medication. Another aspect influencing the industry is the rising number of veterinary professionals.
The Medication segment has shown the growth rate of 5.7 % during (2022 - 2028). The growth of this segment is rising due to numerous new products that veterinary pharmaceutical companies have introduced. For the treatment of arthritis in companion animals, pharmaceuticals are available including NSAIDs, steroids, stem cells, opioids, antibodies, and others. The prevalence of arthritis in pets is rising due to risk factors such as obesity, aging, and dietary deficiencies. As a result, pet owners are more aware of the need to begin timely therapies for their animals.
The Dogs segment is leading the Global Companion Animal Arthritis Market by Animal Type in 2021 thereby, achieving a market value of $2.2 billion by 2028. This is a result of both the high disease prevalence that was observed in dogs and the increased adoption rates for canines. Dogs are the most popular type of companion animals that can be found in the homes of a significant number of people all over the world. The majority of individuals worldwide have been inspired by the COVID-19 pandemic to adopt companion animals for psychological support.
The North America market dominated the Global Companion Animal Arthritis Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1.4 billion by 2028. The Europe market is exhibiting a CAGR of 5.9% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 6.7% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/companion-animal-arthritis-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Boehringer Ingelheim International GmbH, Dechra Pharmaceuticals PLC, Elanco Animal Health, Inc., Zoetis, Inc., Vetoquinol SA, Virbac, Ceva Santé Animale, Eltech K-Laser s.r.l., Norbrook Laboratories Limited, and NexGen Pharmaceuticals, LLC.
By Indication
By Distribution Channel
By Treatment
By Animal Type
By Geography
Companies Profiled
Unique Offerings 
